Clinical Trials Logo

Filter by:
NCT ID: NCT05490771 Active, not recruiting - Clinical trials for Refractory Multiple Myeloma

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Start date: June 20, 2018
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial identifies the effects of copanlisib hydrochloride (copanlisib) in patients whose cancer has a genetic change called PIK3CA mutation. Copanlisib may stop the growth of cancer cells by blocking PIK3, a protein needed for cell growth. Researchers hope to learn if copanlisib will shrink this type of cancer or stop its growth.

NCT ID: NCT05490446 Active, not recruiting - Clinical trials for Myelodysplastic Syndromes

A Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Start date: November 7, 2022
Phase: Phase 2
Study type: Interventional

This purpose of this study is to establish proof of concept of AG-946 in participants with LR-MDS in Phase 2a and to compare the effect of AG-946 versus placebo and to detect a dose response for erythroid response in participants with LR-MDS in Phase 2b.

NCT ID: NCT05489159 Active, not recruiting - Insulin Resistance Clinical Trials

Sleep and IR in Transgender Adolescents

ATP
Start date: October 12, 2022
Phase:
Study type: Observational

Disordered sleep is a health issue with significant impacts on physical and psychological well-being that has increased in prevalence, but its impact on transgender adolescents has not been fully quantified. While there is found to be an impact of sex steroids on sleep, and sex-dependent differences in the impact of sleep duration and quality on insulin resistance (IR), there is limited available information regarding the impact of Gender Affirming Hormone Therapy (GAHT) for transgender individuals on sleep and IR. Our study aims to quantify the impacts of GAHT on sleep and IR in the pediatric transgender population as well as determine the degree of correlation of sleep to IR in this population.

NCT ID: NCT05488782 Active, not recruiting - Depression Clinical Trials

TEAM-Red, a Remotely Delivered Self-management Program for Depressed Black Women at Risk for Hypertension

TEAM-Red
Start date: January 30, 2023
Phase: N/A
Study type: Interventional

The proposed project is a 24-week prospective randomized controlled trial (RCT) evaluating the effects of TargEted MAnageMent Intervention (TEAM, N=25) vs. enhanced wait-list (eWL, N=25) control in depressed young (<50 years) African-American (AA) women at risk for hypertension.

NCT ID: NCT05488626 Active, not recruiting - Clinical trials for Stage III Non-small Cell Lung Cancer

Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer

ARTIA-Lung
Start date: October 20, 2022
Phase: N/A
Study type: Interventional

This is a prospective multi-center randomized clinical trial designed to demonstrate that daily online adaptive radiotherapy with concomitant chemotherapy for stage III non-small cell lung cancer (NSCLC) will result in decreased acute respiratory and esophageal toxicity compared with non-adaptive radiotherapy with concomitant chemotherapy. The timepoint for this assessment will be 1 month following the end of radiotherapy and will use the Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

NCT ID: NCT05488574 Active, not recruiting - Weight Loss Clinical Trials

Effects of Novel Breathing Behavior Modification Yoga Positioning Integrated Program on Weight Loss

Breathing
Start date: September 20, 2022
Phase: N/A
Study type: Interventional

This study is to evaluate the physical and cognitive effects of a 15 min per day novel breathing and mindfulness moving-meditation program on metabolism, cognition, and emotion health. It is thought that the breathing and movement program will increase basal metabolism, facilitate fat loss, and decrease depressive behaviors. Anthropometric, blood chemistries, and cognitive measures of depression, sleep, and hunger will be measured over a two-month interventional program.

NCT ID: NCT05485987 Active, not recruiting - Friedreich Ataxia Clinical Trials

A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia

Start date: October 13, 2022
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to assess the pharmacokinetics (PK) and safety of vatiquinone administered in participants with Friedreich ataxia (FA) younger than 7 years.

NCT ID: NCT05485207 Active, not recruiting - Clinical trials for Interstitial Cystitis

Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome

T3STOPBPS
Start date: April 4, 2022
Phase: Early Phase 1
Study type: Interventional

Interstitial cystitis / bladder pain syndrome (IC/BPS) is a debilitating condition that affects millions of women in the United States. Women suffer from recurring pelvic pain, bladder pressure, painful bladder, urinary frequency (needing to go often) and urgency (feeling a strong need to go). Women are five times more likely to suffer from IC/BPS than men. IC/BPS is a common cause of painful bladder after excluding urinary tract infection. About one-third of women resort to opioids, thus contributing to the current opioid crisis. Sadly, there are no durable treatments and the majority of therapies are not FDA-approved for IC/BPS.

NCT ID: NCT05484999 Active, not recruiting - Clinical trials for Postpartum Depression

The Maternal Well-Being Study

MWB
Start date: May 16, 2022
Phase: N/A
Study type: Interventional

This project aims to understand the local feasibility and acceptability of MamaMeals (a home-delivered nutritious, postpartum meal delivery program) and MamaMatters (a moderated social media-based peer support group) among peripartum women who are eligible for federal supplemental nutrition assistance programs such as The Special Supplemental Nutrition Program for Women, Infants and Children (WIC) or Supplemental Nutrition Assistance Program (SNAP). The investigators will conduct a prospective randomized controlled trial (RCT) of these two interventions among postpartum individuals. Analyses will be performed to determine the relative risk of postpartum depressive or anxiety symptoms (primary outcome) and overall well-being and maternal/infant health (secondary/exploratory outcomes) between groups. Findings from this pilot intervention study will inform a future, large RCT exploring the effectiveness of MamaMeals and/or MamaMatters on reducing postpartum mental health symptoms and cardiovascular morbidity among individuals with food insecurity during and after pregnancy.

NCT ID: NCT05484414 Active, not recruiting - Pain Clinical Trials

Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA)

Start date: May 16, 2022
Phase: Phase 1
Study type: Interventional

This is a two-part randomized, double-blind, placebo-controlled study.